Clinical Trials Logo

Clinical Trial Summary

This study aims to determine the hemato-immunological parameters predictive of the evolution of a Immune thrombocytopenic purpura (ITP) towards chronicity, and to identify possible differences between the child and the adult.


Clinical Trial Description

Immune thrombocytopenic purpura (ITP) is a rare autoimmune thrombocytopenia whose incidence is 2 to 5 cases / 100,000 inhabitants / year. The potentially serious haemorrhagic risk is the major issue of management. A recent international consensus conference classifies PTI according to the duration of thrombocytopenia: acute ITP (<3 months), persistent ITP (3-12 months) and chronic ITP (> 12 months) (Rodeghiero 2009). In the acute or persistent phase, polyvalent immunoglobulins (IVIG) and / or corticosteroids are proposed. In the chronic phase, splenectomy is a possible cure for 70% of patients. No predictor of treatment response is known.

The pathophysiology of ITP is multifactorial: platelet phagocytosis, mediated by autoantibody, macrophages of the reticuloendothelial system, and destruction in the spleen, genetic background and / or environmental factor favoring the role of certain lymphocyte subpopulations, cytotoxic or regulatory T, via their cytokine environment, abnormalities of thrombopoiesis.

ITP affects children as well as adults, but the evolutionary profile is very different. In children, ITP, which is often post-infectious, is acute in 80% of cases, whereas ITP in adults has a chronic evolution in 80% of cases. The primary diagnostic and therapeutic practices are similar. The reasons for these evolutionary differences are not known and little studied.

Is the orientation of the hemato-immunological response observed during the first episode of ITP different in children and adults? Do these differences explain the evolutionary specificities of the two age groups? Are there hematologic parameters predictive of a response to initial treatments? ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04070599
Study type Interventional
Source University Hospital, Bordeaux
Contact
Status Completed
Phase Phase 3
Start date April 12, 2011
Completion date March 5, 2014

See also
  Status Clinical Trial Phase
Recruiting NCT01255332 - Helicobacter Pylori Immune Thrombocytopenic Purpura Phase 2
Completed NCT02077192 - Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT01621204 - A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Phase 3
Completed NCT01719692 - Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia N/A
Completed NCT01730352 - Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Phase 2/Phase 3
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Not yet recruiting NCT05093257 - Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
Completed NCT01672151 - Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia N/A
Completed NCT01390649 - A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Phase 4
Completed NCT01439321 - Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim N/A
Completed NCT00774202 - Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Phase 2/Phase 3
Completed NCT02273960 - Study to Evaluate Safety and Efficacy in Adult Subjects With ITP Phase 1/Phase 2
Not yet recruiting NCT05585944 - " Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura " N/A
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Not yet recruiting NCT05835050 - Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital N/A
Active, not recruiting NCT03395210 - A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) Phase 2
Completed NCT00621894 - Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation Phase 2
Not yet recruiting NCT06444477 - Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
Completed NCT01652599 - Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT Phase 2
Completed NCT00426270 - Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults Phase 3